1. Home
  2. VERU vs UG Comparison

VERU vs UG Comparison

Compare VERU & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • UG
  • Stock Information
  • Founded
  • VERU 1971
  • UG 1942
  • Country
  • VERU United States
  • UG United States
  • Employees
  • VERU N/A
  • UG N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • UG Package Goods/Cosmetics
  • Sector
  • VERU Health Care
  • UG Consumer Discretionary
  • Exchange
  • VERU Nasdaq
  • UG Nasdaq
  • Market Cap
  • VERU 40.6M
  • UG 32.9M
  • IPO Year
  • VERU 1990
  • UG N/A
  • Fundamental
  • Price
  • VERU $2.17
  • UG $5.81
  • Analyst Decision
  • VERU Strong Buy
  • UG
  • Analyst Count
  • VERU 2
  • UG 0
  • Target Price
  • VERU $25.00
  • UG N/A
  • AVG Volume (30 Days)
  • VERU 191.3K
  • UG 10.9K
  • Earning Date
  • VERU 12-15-2025
  • UG 11-06-2025
  • Dividend Yield
  • VERU N/A
  • UG 12.15%
  • EPS Growth
  • VERU N/A
  • UG N/A
  • EPS
  • VERU N/A
  • UG 0.43
  • Revenue
  • VERU $16,886,419.00
  • UG $10,060,322.00
  • Revenue This Year
  • VERU N/A
  • UG N/A
  • Revenue Next Year
  • VERU N/A
  • UG N/A
  • P/E Ratio
  • VERU N/A
  • UG $13.60
  • Revenue Growth
  • VERU 337.24
  • UG N/A
  • 52 Week Low
  • VERU $2.11
  • UG $5.75
  • 52 Week High
  • VERU $14.20
  • UG $11.98
  • Technical
  • Relative Strength Index (RSI)
  • VERU 25.21
  • UG 18.93
  • Support Level
  • VERU $2.11
  • UG $6.05
  • Resistance Level
  • VERU $2.57
  • UG $6.14
  • Average True Range (ATR)
  • VERU 0.20
  • UG 0.22
  • MACD
  • VERU -0.03
  • UG -0.05
  • Stochastic Oscillator
  • VERU 9.33
  • UG 0.00

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

Share on Social Networks: